XBIO Xenetic Biosciences, Inc.
Healthcare$3.07+1.22%ClosedMarket Cap: $5.8M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.00
P/S
1.79
EV/EBITDA
0.69
DCF Value
$-31.96
FCF Yield
-31.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
74.7%
Operating Margin
-75.1%
Net Margin
-70.0%
ROE
-39.3%
ROA
-28.2%
ROIC
-34.4%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $806.9K | 0.0% | $-502.1K | $-456.4K | $— | — |
| Q4 null | $766.3K | 100.0% | $-623.0K | $-579.1K | $— | — |
| FY null | $3.0M | 100.0% | $-2.8M | $-2.7M | $— | — |
| Q3 null | $1.0M | 100.0% | $-544.7K | $-509.9K | $— | — |
| Q2 null | $589.9K | 100.0% | $-724.4K | $-688.7K | $— | — |
| Q1 null | $593.3K | 100.0% | $-942.4K | $-903.1K | $— | — |
| Q4 null | $648.8K | 100.0% | $-1.1M | $-1.1M | $— | — |
| FY null | $2.5M | 100.0% | $-4.2M | $-4.0M | $— | — |
| Q3 null | $614.2K | 100.0% | $-499.5K | $-436.7K | $— | — |
| Q2 null | $726.4K | 100.0% | $-1.3M | $-1.3M | $— | — |
| Q1 null | $510.8K | 100.0% | $-1.3M | $-1.2M | $— | — |
| Q4 2023 | $672.0K | 100.0% | $-1.3M | $-1.2M | $-0.76 | — |